89590-22-7

Usage

InChI:InChI=1/C7H5NO2/c9-5-2-1-3-6-7(5)8-4-10-6/h1-4,9H

Upstream product

• 3163-15-3 2-aminoresorcinol 
• 122-51-0 orthoformic acid triethyl ester 
• 64-18-6 formic acid 
• 77287-34-4 formamide 
• 601-89-8 2-nitroresorcinol 
• 149-73-5 trimethyl orthoformate 
• 107-31-3 Methyl formate 
• 91668-43-8 triethyl chloroformate 
• 634-60-6 2-aminoresorcinol hydrochloride 

Downstream Products

• 166329-37-9 2,6-bis(trimethylsiloxy)phenyl isocyanide 
• 94242-03-2 7-benzoxazoyl 4-methoxycarbanilate 
• 192753-32-5 4-Methoxybenzoxazole 
• 1033810-10-4 4-(2-chloro-4-nitrophenoxy)-1,3-benzoxazole 
• 1620075-80-0 C₂₀H₁₆BrN₃O₄ 
• 1068144-14-8 C₇H₄ClNO₃S 

Relevant academic research and scientific papers

Nucleoside analogs useful as PRMT5 inhibitors

The invention relates to the technical field of biological medicines, and particularly discloses a nucleoside analogue used as a PRMT5 inhibitor. According to the nucleoside analogue as shown in the formula (I) or the pharmaceutically acceptable salt of the nucleoside analogue, the nucleoside analogue or the pharmaceutically acceptable salt of the nucleoside analogue shows relatively high inhibition on the activity of PRMT5 and can be used for preventing and/or treating PRMT5-mediated diseases, and the PRMT5-mediated diseases comprise cell abnormal proliferative diseases.

Ether compound and pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome

The invention relates to an ether compound and a pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome. Specifically, the invention provides a compound as shown in a formula (I), an isomer, a raceme, a prodrug, a solvate, a deuterated substance or a pharmaceutically acceptable salt thereof, and Ar1, Ar2, X, Y and R are defined in the specification.

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors

Pin1 (Protein interacting with NIMA1) is a cis–trans isomerase and promotes the amide bond rotation of phosphoSer/Thr-Pro motifs in its substrates. Inhibition of Pin1 might be a novel strategy for developing anticancer agents. Herein, a series of pyrimidi

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Bicyclic aryl carboxamides and their therapeutic use

Compounds of the formula (i) have therapeutic utility via inhibition of TNF or phosphodiesterase.

Benzofuranyl carbamates

Compounds of the structure; STR1 and pharmaceutically acceptable salts thereof, wherein: R1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, trifluoromethyl, halogen, nitro or hydroxy; X is O, N, S or C; Y is O, N or S; and R2 is H, alkyl, cycloalkyl, aryl or heteroaryl useful in the treatment of ischemic heart disease and hypertriglyceridemia.